Literature DB >> 25339499

Bayesian probability of success for clinical trials using historical data.

Joseph G Ibrahim1, Ming-Hui Chen, Mani Lakshminarayanan, Guanghan F Liu, Joseph F Heyse.   

Abstract

Developing sophisticated statistical methods for go/no-go decisions is crucial for clinical trials, as planning phase III or phase IV trials is costly and time consuming. In this paper, we develop a novel Bayesian methodology for determining the probability of success of a treatment regimen on the basis of the current data of a given trial. We introduce a new criterion for calculating the probability of success that allows for inclusion of covariates as well as allowing for historical data based on the treatment regimen, and patient characteristics. A new class of prior distributions and covariate distributions is developed to achieve this goal. The methodology is quite general and can be used with univariate or multivariate continuous or discrete data, and it generalizes Chuang-Stein's work. This methodology will be invaluable for informing the scientist on the likelihood of success of the compound, while including the information of covariates for patient characteristics in the trial population for planning future pre-market or post-market trials.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  average probability of success; fitting prior; linear regression; marginal likelihood; power prior; simulation; validation prior

Mesh:

Substances:

Year:  2014        PMID: 25339499      PMCID: PMC4676938          DOI: 10.1002/sim.6339

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  10 in total

1.  Maximum likelihood methods for cure rate models with missing covariates.

Authors:  M H Chen; J G Ibrahim
Journal:  Biometrics       Date:  2001-03       Impact factor: 2.571

2.  A new statistical decision rule for single-arm phase II oncology trials.

Authors:  Yiyi Chen; Zunqiu Chen; Motomi Mori
Journal:  Stat Methods Med Res       Date:  2012-03-28       Impact factor: 3.021

3.  Bayesian predictive approach to interim monitoring in clinical trials.

Authors:  Alexei Dmitrienko; Ming-Dauh Wang
Journal:  Stat Med       Date:  2006-07-15       Impact factor: 2.373

4.  Sample size and the probability of a successful trial.

Authors:  Christy Chuang-Stein
Journal:  Pharm Stat       Date:  2006 Oct-Dec       Impact factor: 1.894

5.  Distinct mechanism for antidepressant activity by blockade of central substance P receptors.

Authors:  M S Kramer; N Cutler; J Feighner; R Shrivastava; J Carman; J J Sramek; S A Reines; G Liu; D Snavely; E Wyatt-Knowles; J J Hale; S G Mills; M MacCoss; C J Swain; T Harrison; R G Hill; F Hefti; E M Scolnick; M A Cascieri; G G Chicchi; S Sadowski; A R Williams; L Hewson; D Smith; E J Carlson; R J Hargreaves; N M Rupniak
Journal:  Science       Date:  1998-09-11       Impact factor: 47.728

6.  Evaluating and utilizing probability of study success in clinical development.

Authors:  Yanping Wang; Haoda Fu; Pandurang Kulkarni; Christopher Kaiser
Journal:  Clin Trials       Date:  2013-03-07       Impact factor: 2.486

7.  Bayesian design of noninferiority trials for medical devices using historical data.

Authors:  Ming-Hui Chen; Joseph G Ibrahim; Peter Lam; Alan Yu; Yuanye Zhang
Journal:  Biometrics       Date:  2011-03-01       Impact factor: 2.571

8.  Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder.

Authors:  Martin Keller; Stuart Montgomery; William Ball; Mary Morrison; Duane Snavely; Guanghan Liu; Richard Hargreaves; Jarmo Hietala; Christopher Lines; Katherine Beebe; Scott Reines
Journal:  Biol Psychiatry       Date:  2005-10-24       Impact factor: 13.382

9.  A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax.

Authors:  Larry I Gilderman; James F Lawless; Thomas M Nolen; Tina Sterling; Ruth Z Rutledge; Doreen A Fernsler; Neal Azrolan; Santosh C Sutradhar; William W Wang; Ivan S F Chan; Katia Schlienger; Florian Schödel; Jeffrey L Silber
Journal:  Clin Vaccine Immunol       Date:  2007-12-12

10.  Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older.

Authors:  Boris Kerzner; Alexander V Murray; Eric Cheng; Rudy Ifle; Peter R Harvey; Mark Tomlinson; Julie L Barben; Kimberly Rarrick; Jon E Stek; Mi-Ok Chung; Florian P Schödel; William W B Wang; Jin Xu; Ivan S F Chan; Jeffrey L Silber; Katia Schlienger
Journal:  J Am Geriatr Soc       Date:  2007-10       Impact factor: 5.562

  10 in total
  3 in total

1.  A hierarchical prior for generalized linear models based on predictions for the mean response.

Authors:  Ethan M Alt; Matthew A Psioda; Joseph G Ibrahim
Journal:  Biostatistics       Date:  2022-10-14       Impact factor: 5.279

2.  Left atrial appendage occlusion should be offered only to select atrial fibrillation patients.

Authors:  Muhammad Bilal Munir; Jonathan C Hsu
Journal:  Heart Rhythm O2       Date:  2022-08-22

3.  Assurance in vaccine efficacy clinical trial design based on immunological responses.

Authors:  Andrea Callegaro; Toufik Zahaf; Fabian Tibaldi
Journal:  Biom J       Date:  2021-07-12       Impact factor: 1.715

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.